The link you have chosen leads to a site maintained by a third party over whom Bracco Imaging has no control. As such, Bracco Imaging makes no representation as to the accuracy or any other aspect of the information on this site. The clinical use of Bracco Imaging Products in these pages may not be consistent with the approved indications.
The information on this site is not country specific and may contain information that is outside the approved indication where you practice.
Please contact your local Bracco Imaging representative for the latest Bracco Imaging product information specific to your country.
Do you want to continue?
OK
Cancel
Litteratur
1)
Preparatomtale for MultiHance
2)
Gadobenate dimeglumine (Gd-BOPTA). An overview
3)
Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.
4)
Hepatobiliary MR imaging with gadolinium-based contrast agents.
5)
Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
6)
Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents.
7)
Effect of Gadoxetate Disodium on Arterial Phase Respiratory Waveforms Using a Quantitative Fast Fourier Transformation-Based Analysis.
8)
Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.
9)
Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
10)
Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
11)
Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.
12)
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.
13)
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.
14)
Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.
15)
T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.
16)
A serial dilution study of gadolinium-based MR imaging contrast agents.
17)
Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years.
18)
Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
19)
Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
20)
Bracco Data on File
21)
Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
22)
Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.
23)
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
24)
A Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
25)
Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
26)
Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
27)
Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
28)
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
29)
Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
30)
Prospective cohort study of NSF in patients with stage 3-5 CKD undergoing MRI with gadobenate or gadoteridol.
31)
Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: Is there a real risk in patients with impaired renal function?
32)
Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide.
Acist
ACIST® Medical Systems is a market leader in advanced contrast imaging systems for cardiovascular angiography.
ANSVARSFRASKRIVELSE
For alle produkter eller produkttyper, om det er et legemiddel eller utstyr, som det henvises til på denne nettsiden bør legene nøye gå gjennom produktets pakningsvedlegg, bruksanvisning eller brukerhåndbok før administrasjon til pasient for å sikre riktig bruk av produktet. Den lokale preparatomtalen til de sentrale Bracco Imaging-produktene er tilgjengelig på nett.
Gadolinium-retensjon
Etter administrasjon av gadobensyre kan gadolinium tilbakeholdes i hjernen og annet vev i kroppen (skjelett, lever, nyrer, hud) og forårsake doseavhengige økninger i T1-vektet signalintensitet i hjernen, særlig i dentate nucleus, globus pallidus og thalamus. De kliniske konsekvensene er ukjente. De mulige diagnostiske fordelene ved å bruke MultiHance hos pasienter som trenger gjentatte skanninger bør veies opp mot potensialet for avleiring av gadolinium i hjernen og annet vev.
Nedsatt nyrefunksjon
Før administrasjon av MultiHance anbefales det at alle pasienter screenes for nyredysfunksjon gjennom laboratorietester.
Det har vært rapportert om nefrogen systemisk fibrose (NSF) forbundet med bruk av noen kontrastmidler som inneholder gadolinium hos pasienter med akutt eller kronisk alvorlig nedsatt nyrefunksjon (GFR<30 ml/min/1,73m2).
Pasienter som gjennomgår levertransplantasjoner har spesielt høy risiko siden forekomsten av akutt nyresvikt er høy i denne gruppen. Der det er en mulighet for at NSF kan oppstå med MultiHance, bør det unngås hos pasienter med alvorlig nedsatt nyrefunksjon og hos pasienter i den perioperative levertransplantasjonsperioden med mindre diagnostisk informasjon er avgjørende og ikke tilgjengelig med ikke-kontrastforsterket MRI.
Hemodialyse kort tid etter administrasjon av MultiHance kan være nyttig for å fjerne MultiHance fra kroppen. Det er ingen evidens som støtter igangsetting av hemodialyse for å forebygge eller behandle NSF hos pasienter som ikke allerede gjennomgår hemodialyse.
Eldre
Da renal utskillelse av gadobenatdimeglumin kan være nedsatt hos eldre, er det spesielt viktig å screene pasienter over 65 år for nyredysfunksjon.
